GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Cyclically Adjusted FCF per Share

Swedish Orphan Biovitrum AB (OSTO:SOBI) Cyclically Adjusted FCF per Share : kr2.60 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted free cash flow per share for the three months ended in Mar. 2024 was kr4.392. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr2.60 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Swedish Orphan Biovitrum AB's average Cyclically Adjusted FCF Growth Rate was 33.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Swedish Orphan Biovitrum AB was 5.90% per year. The lowest was 5.90% per year. And the median was 5.90% per year.

As of today (2024-05-14), Swedish Orphan Biovitrum AB's current stock price is kr283.40. Swedish Orphan Biovitrum AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was kr2.60. Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF of today is 109.00.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Swedish Orphan Biovitrum AB was 1493.89. The lowest was 91.51. And the median was 205.53.


Swedish Orphan Biovitrum AB Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Cyclically Adjusted FCF per Share Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.96 -0.43 1.20 2.24 2.22

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 1.83 2.04 2.22 2.60

Competitive Comparison of Swedish Orphan Biovitrum AB's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF falls into.



Swedish Orphan Biovitrum AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.392/130.9575*130.9575
=4.392

Current CPI (Mar. 2024) = 130.9575.

Swedish Orphan Biovitrum AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.331 100.432 -0.432
201409 0.384 100.161 0.502
201412 -0.338 100.225 -0.442
201503 0.544 99.950 0.713
201506 0.243 99.995 0.318
201509 0.535 100.228 0.699
201512 -0.039 100.276 -0.051
201603 0.787 100.751 1.023
201606 -0.192 101.019 -0.249
201609 0.178 101.138 0.230
201612 -0.141 102.022 -0.181
201703 0.875 102.022 1.123
201706 0.562 102.752 0.716
201709 2.024 103.279 2.566
201712 0.765 103.793 0.965
201803 0.926 103.962 1.166
201806 1.908 104.875 2.383
201809 0.702 105.679 0.870
201812 1.804 105.912 2.231
201903 -28.015 105.886 -34.648
201906 3.944 106.742 4.839
201909 3.047 107.214 3.722
201912 0.670 107.766 0.814
202003 5.989 106.563 7.360
202006 5.847 107.498 7.123
202009 -2.530 107.635 -3.078
202012 -5.808 108.296 -7.023
202103 5.141 108.360 6.213
202106 4.443 108.928 5.342
202109 0.770 110.338 0.914
202112 6.021 112.486 7.010
202203 4.775 114.825 5.446
202206 -0.766 118.384 -0.847
202209 0.066 122.296 0.071
202212 5.935 126.365 6.151
202303 -4.068 127.042 -4.193
202306 -1.456 129.407 -1.473
202309 2.020 130.224 2.031
202312 1.713 130.958 1.713
202403 4.392 130.958 4.392

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Swedish Orphan Biovitrum AB  (OSTO:SOBI) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=283.40/2.6
=109.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Swedish Orphan Biovitrum AB was 1493.89. The lowest was 91.51. And the median was 205.53.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Swedish Orphan Biovitrum AB Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines